Clinical trial · Observational
Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
NCT02297958CI-TRIAL-00046868IFFaLCCOcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Carcinoma | Ovarian Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Correlation between cleaved FasL level ans neoadjuvant chemotherapy tumor response
- timeFrame
- surgery
- description
- Main outcome is cleaved FasL level and correlation with neoadjuvant chemotherapy tumor response, evaluated during surgery.
Secondary outcomes (3)
- measure
- Identification of tumoral T cells
- timeFrame
- surgery
- description
- Identification of tumoral T cells with FACS analysis of dissociated tumor. Different T cells will be studies: Treg/Th17/Th1/Th2 using antibodies against: CD45/CD3/CD4/CD25/FOXP3 (Treg), CD45/CD3/CD4/IL17A (Th17), CD45/CD3/CD4/CD8/IL4/INF (TCD8 and LTCD4 Th1 et Th2).
- measure
- Disease Free Survival rate
- timeFrame
- 18 months after surgery
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Pre-Inclusion Criteria: \- Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (CT) Inclusion Criteria: * Pathological ovarian carcinoma diagnosed at pathological analysis after surgery. * Neo adjuvant chemotherapy Exclusion Criteria: * no neo-adjuvant chemotherapy * no ovarian carcinoma at final pathological analysis * less than 18 years old.
References
Publications (0)
Data not yet available
No reference posted for this study.